drugset
drugset / Trial / NCT03576716

Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

NCT03576716 ↗

Phase 1 Completed 19 enrolled University of Washington National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this study is to determine how 25(OH)D3 clearance is affected by vitamin D3 supplementation using a gold standard pharmacokinetic approach.

Timeline

Start
2018-06-01
Primary completion
2019-07-08
Completion
2021-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject D6-25-hydroxyvitamin D3 Unknown — Intravenous

Indications

chronic kidney disease